Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Retrospective aspect of documentation: For patients who have already been changed over to a fixed-dose combination, lung function parameters and CAT (COPD Assessment Test™) score from the time prior to the changeover will be documented.
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female/male of at least 40 years of age
Patient diagnosed with COPD
Patient was changed over within the last 3 months to a fixed-dose combination (FDC) (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol), or there is already the intent to change the patient over to a fixed-dose combination (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol).
Lung function parameters and CAT score from the time prior to the changeover to an FDC are on record (within the last 6 months in the case of patients who have already been changed over) or are determined at the 1st visit (in the case of patients who have not yet been changed over but for whom such a changeover is intended).
Signed declaration of consent
You may not be if
The prescribing information for the fixed-dose combinations (Duaklir® Genuair®, Ulibtro® Breezhaler® or Anoro®) list contraindications for the patient.
Patient is pregnant, plans to become pregnant, or is nursing during the therapy period.
Patient suffers from hypersensitivity to one of the active ingredients of the fixed-dose combinations.
Patient is participating in a clinical trial.
Clareo Health | DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
